Biosimulation Market
Biosimulation Market Size, Share & Trends Analysis By Application (Drug Discovery, Drug Development, Preclinical Testing, and Clinical Trials), By Product (Software and Services), and By End User ( Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Regulatory Authorities, and Others), Forecast Period (2026-2035)
Industry Overview
Biosimulation market was valued at $5.6 billion in 2025 and is projected to reach $37.8 billion by 2035, growing at a CAGR of 21.1% during the forecast period (2026-2035). The industry is growing due to factors like the rise of chronic diseases, increased R&D investments, and the integration of AI and machine learning. Key market drivers include the expansion of cloud-based solutions, the use of virtual clinical trials to reduce costs, and growing regulatory support for model-informed drug development.
Market Dynamics
Rising Need to Reduce Drug Development Costs and Failure Rates
One of the strongest drivers of the biosimulation market is the high attrition rate and escalating cost of drug development. As reported, approx. 90?% of drug candidates fail during phases?I–III clinical trials, which places enormous cost and time pressure on pharma/biotech companies. Biosimulation tools such as physiologically?based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models offer a way to simulate drug behaviour, anticipate toxicity or efficacy issues before going into full clinical trials. This capacity to de?risk early development enables companies to shorten timelines, reduce costly late?stage failures and optimise dosing regimens, thereby spurring adoption of biosimulation solutions.
Growing Adoption of In?Silico Modelling and Regulatory Acceptance
Another major growth driver is the increasing recognition by regulatory agencies (such as the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)) of model?informed drug development (MIDD) and biosimulation as credible tools in regulatory submissions. With regulations and guidance evolving to support simulation for pharmacokinetics/pharmacodynamics (PK/PD), toxicity prediction and trial design, pharmaceutical organisations are more willing to integrate biosimulation into their workflows. Moreover, trends such as virtual twin modelling, AI?integrated simulation platforms and cloud?delivered high?performance computing further facilitate the adoption and scalability of biosimulation technologies.
Increasing Prevalence of Chronic Diseases, Precision Medicine Demand & Digital Healthcare Transformation
Lastly, the growing burden of chronic diseases (e.g., oncology, cardiovascular, CNS disorders), together with the shift toward precision medicine and digital?health ecosystems, is driving the need for advanced simulation tools. Biosimulation enables the modelling of patient?specific treatment responses, virtual patient populations and adaptive trial designs, capabilities highly valued in precision medicine frameworks. Meanwhile, the ongoing digitalisation of healthcare and R&D, rising investment into biotech innovation, and the demand for rapid development of novel therapeutics all support the biosimulation market’s growth. These factors collectively create strong tailwinds for vendors and service providers in the biosimulation ecosystem.
Market Segmentation
- Based on the application, the market is segmented into drug discovery, drug development, preclinical testing, and clinical trials.
- Based on the product, the market is segmented into software and services
- Based on the end user, the market is segmented into biotechnology and pharmaceutical companies, contract research organizations (CROS), regulatory authorities, and others.
Software Segment to Grow at a Considerable Market Share
The software segment is the largest in the global biosimulation market, commanding the highest share in 2025. Software solutions account for over 65–70% of total market revenue, primarily due to their critical role in enabling in-silico modelling, simulation, and analysis across drug discovery and development processes. These platforms include physiologically based pharmacokinetic (PBPK) modelling software, quantitative systems pharmacology (QSP) tools, pharmacokinetic/pharmacodynamic (PK/PD) simulation platforms, and virtual patient modelling systems. The dominance of software is driven by its ability to streamline preclinical and clinical development, reduce the reliance on costly laboratory experiments, and support decision-making in early-stage drug development.
Pharmaceutical and biotechnology companies increasingly invest in advanced biosimulation software to optimize dosing regimens, predict toxicity, and improve efficacy profiles before clinical trials. Additionally, the adoption of cloud-based software solutions, AI-integrated platforms, and user-friendly interfaces has made these tools more accessible to organizations of all sizes, further boosting their market share. Software’s flexibility, scalability, and integration with digital R&D ecosystems have made it indispensable in the modern biosimulation landscape, solidifying its position as the leading segment by revenue.
Drug Discovery: A Key Segment in Market Growth
The drug discovery and lead-optimization application segment is the key growth driver in the global biosimulation market. This segment is witnessing the fastest adoption, with a projected high CAGR over the forecast period, due to the increasing need for efficient, cost-effective, and accelerated drug development pipelines. Biosimulation technologies in this segment allow researchers to virtually test multiple compounds, predict pharmacokinetics, pharmacodynamics, and toxicity profiles, and select the most promising candidates for clinical trials. The growing prevalence of chronic diseases, rising demand for precision medicine, and the shift toward model-informed drug development (MIDD) are fueling adoption in drug discovery applications.
Moreover, regulatory agencies, including the FDA and EMA, are increasingly recognizing biosimulation data in drug approval processes, which encourages pharmaceutical companies to integrate simulation early in drug design. The ability to reduce time-to-market, optimize compound selection, and minimize clinical trial failures makes drug discovery the most strategically important segment for market expansion. As more organizations adopt in-silico modelling and virtual trials, the drug discovery application segment is poised to maintain its highest growth, driving overall expansion of the global biosimulation market.
Regional Outlook
The global biosimulation market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global biosimulation market, holding the largest share in 2025 and expected to maintain its leadership throughout the forecast period. This dominance is driven by the country’s advanced pharmaceutical and biotechnology sectors, high R&D expenditure, and early adoption of in-silico modelling, quantitative systems pharmacology (QSP), and physiologically based pharmacokinetic (PBPK) simulation tools. The U.S. hosts leading biosimulation companies such as Certara, Simulations Plus, and Schrödinger, along with world-class research institutions and contract research organizations (CROs) that foster innovation and technology adoption. Regulatory support from the U.S. Food & Drug Administration (FDA) for model-informed drug development (MIDD) further accelerates the use of biosimulation in clinical trial design, dosing optimization, and reducing late-stage drug failures.
Additionally, rising investment in digital healthcare, AI-driven drug discovery, and precision medicine, combined with the increasing prevalence of chronic diseases and oncology research, strengthens the country’s market position. Strong collaborations between academia, industry, and government initiatives also enhance the development and deployment of biosimulation platforms. Collectively, these factors ensure that the United States remains the dominant player in the global biosimulation market, commanding a major share and setting the pace for innovation and growth globally.
Market Players Outlook
The major companies operating in the global biosimulation market include Certara, Inc., Dassault Systèmes SE, Genedata AG, Schrödinger, Inc., Simulations Plus, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In October 2025, Certara, Inc. launched Certara IQ, an AI-powered Quantitative Systems Pharmacology (QSP) platform aimed at enhancing drug development by integrating AI with biosimulation. This solution seeks to improve R&D productivity, mitigate risks, and deepen insights into complex therapies. With the demand for QSP in FDA submissions growing, Certara IQ addresses historical limitations by simplifying workflows and enhancing reproducibility. Key features include an intuitive interface for building models, a comprehensive repository of validated models, and a high-performance simulation engine that accelerates model creation and decision-making processes.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global biosimulation market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Biosimulation Market Sales Analysis – Application | Product | End User ($ Million)
- Biosimulation Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Biosimulation Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global Biosimulation Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Biosimulation Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Biosimulation Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Biosimulation Market Revenue and Share by Manufacturers
- Biosimulation Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Certara, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Dassault Systèmes SE
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Genedata AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Schrödinger, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Simulations Plus, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Certara, Inc.
- Key Company Analysis
- Global Biosimulation Market Sales Analysis by Application ($ Million)
- Drug Discovery
- Drug Development
- Preclinical Testing
- Clinical Trials
- Global Biosimulation Market Sales Analysis by Product ($ Million)
- Software
- Molecular Modeling & Simulation Software
- Clinical Trial Design Software
- PK/PD Modeling and Simulation Software
- Pbpk Modeling and Simulation Software
- Toxicity Prediction Software
- Other Software
- Services
- Contract Services
- Consulting
- Others (Implementation, Training, & Support)
- Software
- Global Biosimulation Market Sales Analysis by End User ($ Million)
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Regulatory Authorities
- Others
- Regional Analysis
- North American Biosimulation Market Sales Analysis – Application | Source | End User | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Biosimulation Market Sales Analysis – Application | Source | End User | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Biosimulation Market Sales Analysis – Application | Source | End User | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Biosimulation Market Sales Analysis – Application | Source | End User | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Advanced Chemistry Development, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Atomwise, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BioSymetrics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cadence Design Systems, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cellworks Group Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Certara, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chemical Computing Group ULC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Dassault Systèmes SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Entelos, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Genedata AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- In Silico Biosciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Insilico Medicine, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Instem Group of Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- LeadInvent Technologies Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- LeadScope, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Physiomics Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Rhenovia Pharma SAS
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Schrödinger, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Simulations Plus, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- VeriSIM Life Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Advanced Chemistry Development, Inc.
1. Global Biosimulation Market Research and Analysis by Application, 2025–2035 ($ Million)
2. Global Biosimulation In Drug Discovery Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Biosimulation In Drug Development Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Biosimulation In Preclinical Testing Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Biosimulation In Clinical Trials Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Biosimulation Market Research and Analysis by Product, 2025–2035 ($ Million)
7. Global Biosimulation Software Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Molecular Modeling & Simulation Software Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Clinical Trial Design Software Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global PK/PD Modeling and Simulation Software Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Toxicity Prediction Software Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Biosimulation Services Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Biosimulation Contract Services Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Biosimulation Consulting Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Biosimulation Other Services Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Biosimulation Market Research and Analysis by End Usert, 2025–2035 ($ Million)
17. Global Biosimulation For Biotechnology and Pharmaceutical Companies Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Biosimulation For Contract Research Organizations (CROs) Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Biosimulation For Regulatory Authorities Market Research and Analysis by Region, 2025–2035 ($ Million)
20. Global Biosimulation For Other End User Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Global Biosimulation Market Research and Analysis by Region, 2025–2035 ($ Million)
22. North American Biosimulation Market Research and Analysis by Country, 2025–2035 ($ Million)
23. North American Biosimulation Market Research and Analysis by Application, 2025–2035 ($ Million)
24. North American Biosimulation Market Research and Analysis by Product Type, 2025–2035 ($ Million)
25. North American Biosimulation Market Research and Analysis by End User, 2025–2035 ($ Million)
26. European Biosimulation Market Research and Analysis by Country, 2025–2035 ($ Million)
27. European Biosimulation Market Research and Analysis by Application, 2025–2035 ($ Million)
28. European Biosimulation Market Research and Analysis by Product Type, 2025–2035 ($ Million)
29. European Biosimulation Market Research and Analysis by End User, 2025–2035 ($ Million)
30. Asia-Pacific Biosimulation Market Research and Analysis by Country, 2025–2035 ($ Million)
31. Asia-Pacific Biosimulation Market Research and Analysis by Application, 2025–2035 ($ Million)
32. Asia-Pacific Biosimulation Market Research and Analysis by Product Type, 2025–2035 ($ Million)
33. Asia-Pacific Biosimulation Market Research and Analysis by End User, 2025–2035 ($ Million)
34. Rest of the World Biosimulation Market Research and Analysis by Region, 2025–2035 ($ Million)
35. Rest of the World Biosimulation Market Research and Analysis by Application, 2025–2035 ($ Million)
36. Rest of the World Biosimulation Market Research and Analysis by Product Type, 2025–2035 ($ Million)
37. Rest of the World Biosimulation Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global Biosimulation Market Share by Application, 2025 Vs 2035 (%)
2. Global Biosimulation in Drug Discovery Market Share by Region, 2025 Vs 2035 (%)
3. Global Biosimulation in Drug Development Market Share by Region, 2025 Vs 2035 (%)
4. Global Biosimulation in Preclinical Testing Market Share by Region, 2025 Vs 2035 (%)
5. Global Biosimulation in Clinical Trials Market Share by Region, 2025 Vs 2035 (%)
6. Global Biosimulation Market Share by Product, 2025 Vs 2035 (%)
7. Global Biosimulation Software Market Share by Region, 2025 Vs 2035 (%)
8. Global Molecular Modeling & Simulation Software Market Share by Region, 2025 Vs 2035 (%)
9. Global Clinical Trial Design Software Market Share by Region, 2025 Vs 2035 (%)
10. Global PBPK Modeling and Simulation Software Market Share by Region, 2025 Vs 2035 (%)
11. Global Biosimulation Toxicity Prediction Software Market Share by Region, 2025 Vs 2035 (%)
12. Global Biosimulation Services Market Share by Region, 2025 Vs 2035 (%)
13. Global Biosimulation Contract Services Market Share by Region, 2025 Vs 2035 (%)
14. Global Biosimulation Consulting Market Share by Region, 2025 Vs 2035 (%)
15. Global Biosimulation Other Services Market Share by Region, 2025 Vs 2035 (%)
16. Global Biosimulation Market Share by End User, 2025 Vs 2035 (%)
17. Global Biosimulation for Biotechnology and Pharmaceutical Companies Market Share by Region, 2025 Vs 2035 (%)
18. Global Biosimulation for Contract Research Organizations (CROs) Market Share by Region, 2025 Vs 2035 (%)
19. Global Biosimulation for Regulatory Authorities Market Share by Region, 2025 Vs 2035 (%)
20. Global Biosimulation for Other End Users Market Share by Region, 2025 Vs 2035 (%)
21. Global Biosimulation Market Share by Region, 2025 Vs 2035 (%)
22. US Biosimulation Market Size, 2025–2035 ($ Million)
23. Canada Biosimulation Market Size, 2025–2035 ($ Million)
24. UK Biosimulation Market Size, 2025–2035 ($ Million)
25. France Biosimulation Market Size, 2025–2035 ($ Million)
26. Germany Biosimulation Market Size, 2025–2035 ($ Million)
27. Italy Biosimulation Market Size, 2025–2035 ($ Million)
28. Spain Biosimulation Market Size, 2025–2035 ($ Million)
29. Russia Biosimulation Market Size, 2025–2035 ($ Million)
30. Rest of Europe Biosimulation Market Size, 2025–2035 ($ Million)
31. India Biosimulation Market Size, 2025–2035 ($ Million)
32. China Biosimulation Market Size, 2025–2035 ($ Million)
33. Japan Biosimulation Market Size, 2025–2035 ($ Million)
34. South Korea Biosimulation Market Size, 2025–2035 ($ Million)
35. Australia and New Zealand Biosimulation Market Size, 2025–2035 ($ Million)
36. ASEAN Economies Biosimulation Market Size, 2025–2035 ($ Million)
37. Rest of Asia-Pacific Biosimulation Market Size, 2025–2035 ($ Million)
38. Latin America Biosimulation Market Size, 2025–2035 ($ Million)
39. Middle East and Africa Biosimulation Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
